Wellington Management Group LLP Acquires Shares of 2,060,173 Savara Inc (NASDAQ:SVRA)

Wellington Management Group LLP bought a new position in shares of Savara Inc (NASDAQ:SVRA) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 2,060,173 shares of the company’s stock, valued at approximately $9,683,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. AJOVista LLC purchased a new stake in Savara during the 4th quarter worth $40,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Savara during the fourth quarter valued at about $74,000. Tower Research Capital LLC TRC grew its stake in shares of Savara by 665.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company’s stock valued at $92,000 after acquiring an additional 16,959 shares in the last quarter. Algert Global LLC increased its position in shares of Savara by 128.3% during the third quarter. Algert Global LLC now owns 36,640 shares of the company’s stock worth $138,000 after acquiring an additional 20,590 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Savara by 34.2% in the fourth quarter. SG Americas Securities LLC now owns 49,862 shares of the company’s stock worth $234,000 after acquiring an additional 12,720 shares in the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

SVRA has been the subject of a number of recent analyst reports. JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of Savara in a research note on Monday, May 6th. Evercore ISI dropped their price target on shares of Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, May 16th. Oppenheimer upped their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday. Guggenheim raised their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Piper Sandler upped their target price on shares of Savara from $7.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $11.00.

Savara Stock Performance

Savara stock opened at $3.81 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. Savara Inc has a 12 month low of $2.63 and a 12 month high of $5.70. The company has a fifty day moving average price of $4.32 and a two-hundred day moving average price of $4.63. The company has a market cap of $526.50 million, a PE ratio of -10.30 and a beta of 0.70.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Research analysts expect that Savara Inc will post -0.41 earnings per share for the current year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.